Navigation Links
MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification

Company to Report Interim Celgosivir 4-Week Viral Kinetics Study Data on

Monday December 3, 2007

VANCOUVER and SAN DIEGO, Nov. 30 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, December 13, 2007 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the second fiscal quarter ended October 31, 2007 and provide an update on company activities. To participate in the conference call, please dial 416-644-3418 or 1-800-732-1073. The call will be available for replay until December 27, 2007 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21255722 (followed by the number sign). The live and archived webcast can be accessed through the company's website at for the next 90 days.

Additionally, the Company will report interim 4-week data from a Phase II viral kinetics combination study of celgosivir in patients with chronic HCV (genotype 1) infection on Monday December 3, 2007.


MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C infections (Phase II and preclinical), the prevention of catheter-related infections (Phase III) and the treatment of dermatological diseases (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233,; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210,

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... -- Clintrax Global, Inc., a worldwide provider of clinical research services headquartered ... the company has set a new quarterly earnings record in Q3 ... posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , with ...
(Date:11/24/2015)... 2015 --> ... released by Transparency Market Research, the global non-invasive prenatal ... of 17.5% during the period between 2014 and 2022. ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... market to reach a valuation of US$2.38 bn by ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
Breaking Biology News(10 mins):